Today: 17 May 2026
Why AleAnna (ANNA) Stock Price Jumped 87% as Europe Gas Shock Hit Markets
21 March 2026
1 min read

Why AleAnna (ANNA) Stock Price Jumped 87% as Europe Gas Shock Hit Markets

NEW YORK, March 21, 2026, 13:14 EDT

AleAnna finished Friday up 86.8% at $7.07, after hitting an intraday peak of $7.70. Volume spiked, with about 115.4 million shares traded.

This shift has weight: Europe’s chasing gas supplies once more. On Thursday, benchmark European gas prices soared up to 35% after strikes hit major Middle East gas facilities. The European Union, in response, called on members to ease gas-storage goals down to 80% in hopes of steadying the market.

AleAnna focuses on onshore natural gas and renewable natural gas projects in Italy. The company reported roughly $13.9 million in revenue from Longanesi gas sales during the first nine months of 2025, following initial production in March. Shell Energy Europe remains the sole buyer for AleAnna’s portion of the output.

Last week, the company pushed the narrative further. AleAnna reported that an independent assessment by DeGolyer and MacNaughton bumped up its proved reserves for year-end 2025 by 47%, reaching 25.8 billion cubic feet — that’s gas considered almost certain to be recovered. CEO Marco Brun labeled it a “substantial increase” and said the move sharpens production visibility. GlobeNewswire

The same setup has pushed up major gas stocks as well. Shares of Cheniere Energy and Venture Global jumped earlier this week, after QatarEnergy warned that attacks might knock out close to 20% of Qatari LNG exports for as long as three to five years. Wood Mackenzie’s Tom Marzec-Manser weighed in, saying European and Asian gas prices probably “remain elevated for longer.” Reuters

AleAnna hasn’t strayed from its message in recent months. Back in February, Chairman Graham Van’t Hoff called the EU’s plan to end Russian gas a “decisive policy inflection,” insisting Italy’s own fields and pipelines could become a steady source. GlobeNewswire

The pitfalls are clear. In its most recent quarterly report, AleAnna flagged that its prospects hinge on securing funding, navigating Italian regulations, and moving forward with local field work. The company also pointed out significant gaps in its financial reporting controls.

Friday’s surge stood out, bucking the wider market slide. The Nasdaq slid 2.01%, while the S&P 500 lost 1.51% with investors rattled by Iran war-driven inflation worries. But energy shares in the S&P 500 still notched their 13th consecutive weekly advance.

Stock Market Today

  • Monster Beverage (MNST) Stock Near Fair Value After Multi-Year Gains
    May 16, 2026, 9:18 PM EDT. Monster Beverage (MNST) has delivered strong returns, rising nearly 89% over five years. The stock recently traded at around $87, modestly above its estimated intrinsic value of $80.02 based on a Discounted Cash Flow (DCF) model. This valuation approach projects Monster's free cash flow growing from $1.94 billion to over $3 billion by 2030. Despite impressive share price gains, the DCF suggests Monster is roughly 8.8% overvalued, indicating current prices are close to fair value rather than significantly overpriced. While the company's position in the US energy drink market supports growth prospects, its valuation score was 0 out of 6 on standard metrics, urging caution for new investors. Traders should monitor valuation shifts and market developments to time entries appropriately.

Latest articles

Joby Aviation Slides Monday With Air-Taxi in Focus

Joby Aviation Slides Monday With Air-Taxi in Focus

17 May 2026
Joby Aviation shares closed Friday at $10.36, down 2.6% for the day and 4.7% for the week. CEO JoeBen Bevirt-linked trusts sold over 421,000 shares under a preset 10b5-1 plan, filings showed. The stock traded between $10.04 and $10.58 during a volatile week. Broader markets and eVTOL sector peers also declined.
ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

ImmunityBio’s BCG Agreement Puts Monday’s Trading in Focus

17 May 2026
ImmunityBio closed at $7.97 Friday, down 2.2% after announcing exclusive U.S. rights to Japan BCG Laboratory’s Tokyo-172 strain for bladder cancer therapy. The Tokyo strain remains investigational in the U.S. and is not FDA-approved. Nasdaq was closed for the weekend; the next trading session is Monday. ImmunityBio’s Q1 product revenue rose to $44.2 million with $380.9 million in cash and securities.
Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

Infleqtion Stock Just Took a Hit After Record Revenue — What Could Move INFQ Next

17 May 2026
Infleqtion Inc. shares fell 10.95% to $12.44 Friday, capping a rough week for quantum tech stocks. The company reported a first-quarter net loss of $30.3 million on $9.5 million in revenue, with 85% from government contracts. Infleqtion launched a new RF sensing platform and raised its 2026 revenue outlook, but warned of continued operating losses.
Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

Synopsys Shares Dropped for the Week, Looking to May 27 for Direction

17 May 2026
Synopsys shares fell 1.49% Friday to $502.42, ending the week down 2.72% amid a broad tech selloff and news that Coatue Management cut its stake by 54%. The Nasdaq Composite dropped 1.54% Friday, while the Philadelphia semiconductor index slid 4%. Synopsys will report fiscal Q2 results after the market closes on May 27. Wells Fargo and Citigroup raised their price targets for the stock earlier in the week.
Welltower Stock Slides Nearly 5% as Fed Hike Fears Test Senior Housing Rally
Previous Story

Welltower Stock Slides Nearly 5% as Fed Hike Fears Test Senior Housing Rally

Constellation Energy stock price drops 11% as $5 billion LS Power sale sharpens Calpine focus
Next Story

Constellation Energy stock price drops 11% as $5 billion LS Power sale sharpens Calpine focus

Go toTop